Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy

Conditions:   Transitional Cell Tumor;   Hepatoblastoma;   Liver Cancer;   Pediatric Solid Tumor;   Pediatric Cancer Intervention:   Drug: PD-1 inhibitor Sponsor:   RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials